Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (33)
Swetha Subramaniyan, Beena Briget Kuriakose, Sakeena Mushfiq, Narayanaswamy Marimuthu Prabhu & Karthikeyan Muthusamy. (2023) Gene Signals and SNPs Associated with Parkinson’s Disease: A Nutrigenomics and Computational Prospective Insights. Neuroscience 533, pages 77-95.
Crossref
Crossref
Sadegh Moradi Vastegani, Ava Nasrolahi, Shahab Ghaderi, Rafie Belali, Masome Rashno, Maryam Farzaneh & Seyed Esmaeil Khoshnam. (2023) Mitochondrial Dysfunction and Parkinson’s Disease: Pathogenesis and Therapeutic Strategies. Neurochemical Research 48:8, pages 2285-2308.
Crossref
Crossref
Zijian Zheng, Shushan Zhang, Hanwen Zhang, Zhongzheng Gao, Xiangrong Wang, Xinjie Liu, Cheng Xue, Longping Yao & Guohui Lu. (2022) Mechanisms of Autoimmune Cell in DA Neuron Apoptosis of Parkinson’s Disease: Recent Advancement. Oxidative Medicine and Cellular Longevity 2022, pages 1-20.
Crossref
Crossref
Isabella Russo, Luigi Bubacco & Elisa Greggio. (2022) LRRK2 as a target for modulating immune system responses. Neurobiology of Disease 169, pages 105724.
Crossref
Crossref
Sachin Kumar, Tapan Behl, Aayush Sehgal, Sridevi Chigurupati, Sukhbir Singh, Vasudevan Mani, Maha Aldubayan, Ahmed Alhowail, Satvinder Kaur, Saurabh Bhatia, Ahmed Al-Harrasi, Vetriselvan Subramaniyan, Shivkanya Fuloria, Neeraj Kumar Fuloria, Mahendran Sekar & Mohamed M. Abdel Daim. (2022) Exploring the focal role of LRRK2 kinase in Parkinson’s disease. Environmental Science and Pollution Research 29:22, pages 32368-32382.
Crossref
Crossref
Alicia Garrido, Enrique Santamaría, Joaquín Fernández‐Irigoyen, Marta Soto, Cristina Simonet, Manel Fernández, Donina Obiang, Eduardo Tolosa, María‐José Martí, Shalini Padmanabhan, Cristina Malagelada, Mario Ezquerra & Rubén Fernández‐Santiago. (2022)
Differential Phospho‐Signatures in Blood Cells Identify
LRRK2
G2019S
Carriers in Parkinson's Disease
. Movement Disorders 37:5, pages 1004-1015.
Crossref
Crossref
Seung Hyun Lee, Sang-Min Park, Sang Seok Yeo, Ojin Kwon, Mi-Kyung Lee, Horyong Yoo, Eun Kyoung Ahn, Jae Young Jang & Jung-Hee Jang. (2022) Parkinson’s Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering. Diagnostics 12:1, pages 112.
Crossref
Crossref
Boba Kotlica, Momčilo Ristanović & Ivana Novaković. (2022) Analysis of rs34637584 polymorphism in the LRRK2 gene in patients with Parkinson's disease. Medicinski podmladak 73:3, pages 33-37.
Crossref
Crossref
Theodora Ntetsika, Paraskevi-Evita Papathoma & Ioanna Markaki. (2021) Novel targeted therapies for Parkinson’s disease. Molecular Medicine 27:1.
Crossref
Crossref
Ramón Cacabelos, Iván Carrera, Olaia Martínez, Ramón Alejo, Lucía Fernández‐Novoa, Pablo Cacabelos, Lola Corzo, Susana Rodríguez, Margarita Alcaraz, Laura Nebril, Iván Tellado, Natalia Cacabelos, Rocío Pego, Vinogran Naidoo & Juan C. Carril. (2021) Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Medicinal Research Reviews 41:5, pages 2841-2886.
Crossref
Crossref
Douglas S. Williamson, Garrick P. Smith, Gitte K. Mikkelsen, Thomas Jensen, Pamela Acheson-DossangLassina Badolo, Simon T. Bedford, Victoria ChellI-Jen Chen, Pawel Dokurno, Morten Hentzer, Samantha NewlandStuart C. RayTerry ShawAllan E. Surgenor, Lindsey TerryYikang Wang & Kenneth V. Christensen. (2021)
Design and Synthesis of Pyrrolo[2,3-
d
]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate
. Journal of Medicinal Chemistry 64:14, pages 10312-10332.
Crossref
Crossref
Longping Yao, Jiayu Wu, Sumeyye Koc & Guohui Lu. (2021) Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Ye Zhao, Shikara Keshiya, Gayathri Perera, Lauren Schramko, Glenda M. Halliday & Nicolas Dzamko. (2020) LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiology of Disease 144, pages 105049.
Crossref
Crossref
Theresa Lüth, Inke R. König, Anne Grünewald, Meike Kasten, Christine Klein, Faycel Hentati, Matthew Farrer & Joanne Trinh. (2020)
Age at Onset of
LRRK2
p.
Gly2019Ser
Is Related to Environmental and Lifestyle Factors
. Movement Disorders 35:10, pages 1854-1858.
Crossref
Crossref
Ling Ling Chua, Patrick Ho, Joanne Toh & Eng-King Tan. (2020) Chetomin rescues pathogenic phenotype of LRRK2 mutation in drosophila. Aging 12:18, pages 18561-18570.
Crossref
Crossref
Joseph Jankovic & Eng King Tan. (2020) Parkinson’s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry 91:8, pages 795-808.
Crossref
Crossref
Khalid Bashir Dar, Aashiq Hussain Bhat, Shajrul Amin, Bilal Ahmad Reshi, Mohammad Afzal Zargar, Akbar Masood & Showkat Ahmad Ganie. (2019) Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration. Cellular and Molecular Neurobiology 40:3, pages 313-345.
Crossref
Crossref
Josefa Zaldivar-Diez, Lingling Li, Ana M. Garcia, Wen-Ning Zhao, Cristina Medina-Menendez, Stephen. J. Haggarty, Carmen Gil, Aixa V. Morales & Ana Martinez. (2019) Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. Journal of Medicinal Chemistry 63:5, pages 2638-2655.
Crossref
Crossref
Eduardo Tolosa, Miquel Vila, Christine Klein & Olivier Rascol. (2020) LRRK2 in Parkinson disease: challenges of clinical trials. Nature Reviews Neurology 16:2, pages 97-107.
Crossref
Crossref
Shen Gu, Jun Chen, Qun Zhou, Minghao Yan, Jian He, Xiaodong Han & Yudong Qiu. (2019) LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro. Digestive Diseases and Sciences 65:2, pages 500-508.
Crossref
Crossref
Aroma Agape Gopalai, Jia Lun Lim, Hui‐Hua Li, Yi Zhao, Thien Thien Lim, Gaik B. Eow, Santhi Puvanarajah, Shanthi Viswanathan, Mohamed Ibrahim Norlinah, Zariah Abdul Aziz, Soo Kun Lim, Chong Tin Tan, Ai Huey Tan, Shen‐Yang Lim, Eng‐King Tan & Azlina Ahmad Annuar. (2019)
LRRK2
N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A case–control association study for Parkinson's disease
. Molecular Genetics & Genomic Medicine 7:11.
Crossref
Crossref
Stella C. Junqueira, Eduarda G.Z. Centeno, Kevin A. Wilkinson & Helena Cimarosti. (2019) Post-translational modifications of Parkinson's disease-related proteins: Phosphorylation, SUMOylation and Ubiquitination. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1865:8, pages 2001-2007.
Crossref
Crossref
Wongi Seol, Daleum Nam & Ilhong Son. (2019) Rab GTPases as Physiological Substrates of LRRK2 Kinase. Experimental Neurobiology 28:2, pages 134-145.
Crossref
Crossref
Meng Huang, Xiao Gu & Xiaoling Gao. 2019. Brain Targeted Drug Delivery System. Brain Targeted Drug Delivery System
321
356
.
Silvia Bolognin, Marie Fossépré, Xiaobing Qing, Javier Jarazo, Janez Ščančar, Edinson Lucumi Moreno, Sarah L. Nickels, Kobi Wasner, Nassima Ouzren, Jonas Walter, Anne Grünewald, Enrico Glaab, Luis Salamanca, Ronan M. T. Fleming, Paul M. A. Antony & Jens C. Schwamborn. (2019) 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. Advanced Science 6:1, pages 1800927.
Crossref
Crossref
Emmanuel Quansah, Wouter Peelaerts, J. William Langston, David K. Simon, Jerry Colca & Patrik Brundin. (2018) Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. Molecular Neurodegeneration 13:1.
Crossref
Crossref
Ye Zhao, Shikara Keshiya, Farzaneh Atashrazm, Jianqun Gao, Lars M. Ittner, Dario R. Alessi, Glenda M. Halliday, Yuhong Fu & Nicolas Dzamko. (2018) Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. Neurobiology of Disease 120, pages 76-87.
Crossref
Crossref
Palak AminMarcus FlorezAyaz NajafovHeling PanJiefei GengDimitry OfengeimSlawomir A. DziedzicHuibing WangVica Jean BarrettYasushi ItoMatthew J. LaVoie & Junying Yuan. (2018) Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNFα-mediated apoptosis. Proceedings of the National Academy of Sciences 115:26.
Crossref
Crossref
Elaine GY Chew, Jia Nee Foo & Eng‐King Tan. (2018) Identifying genes in Parkinson disease: state of the art. Medical Journal of Australia 208:9, pages 381-382.
Crossref
Crossref
Fleur M. Ferguson & Nathanael S. Gray. (2018) Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery 17:5, pages 353-377.
Crossref
Crossref
Anthony E. Lang & Alberto J. Espay. (2018) Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders 33:5, pages 660-677.
Crossref
Crossref
Sun-Hwa Lee & Kyoungho Suk. (2017) Emerging roles of protein kinases in microglia-mediated neuroinflammation. Biochemical Pharmacology 146, pages 1-9.
Crossref
Crossref
Douglas S. Williamson, Garrick P. Smith, Pamela Acheson-Dossang, Simon T. Bedford, Victoria Chell, I-Jen Chen, Justus C. A. Daechsel, Zoe Daniels, Laurent David, Pawel Dokurno, Morten Hentzer, Martin C. Herzig, Roderick E. Hubbard, Jonathan D. Moore, James B. Murray, Samantha Newland, Stuart C. Ray, Terry Shaw, Allan E. Surgenor, Lindsey Terry, Kenneth Thirstrup, Yikang Wang & Kenneth V. Christensen. (2017) Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). Journal of Medicinal Chemistry 60:21, pages 8945-8962.
Crossref
Crossref